Antiemetics Clinical Trials

All Categories Medications / Interventions » Aa » Antiemetics

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens

Condition: Cataract
Interventions: Drug: 40 mg/mL Dexamethasone phosphate ophthalmic solution; Drug: 100 mM sodium citrate buffer solution
Sponsors: Eyegate Pharmaceuticals, Inc.; Eyegate Pharmaceuticals, Inc.
Not yet recruiting - verified May 2012
Stress Management Training for Latinas Receiving Chemotherapy

Conditions: Cancer; Stress
Interventions: Behavioral: Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT); Behavioral: Usual Care Only
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; American Cancer Society; University of Miami
Recruiting - verified May 2012
Comparing Subsartorial Saphenous Nerve Blocks With and Without Dexamethasone for Anterior Cruciate Ligament Reconstruction

Conditions: Anterior Cruciate Ligament Reconstruction; Regional Anesthesia, Saphenous Nerve Block
Interventions: Drug: Bupivacaine Only; Drug: Bupivacaine with 2 ml of Dexamethasone; Drug: Bupivacaine with 4 mg of Dexamethasone
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York
Not yet recruiting - verified April 2012
Pharmacogenetic Treatments for Alcoholism

Condition: Alcoholism
Interventions: Drug: Ondansetron + Brief Behavioral Enhancement Treatment; Drug: Placebo + Brief Behavioral Enhancement Treatment
Sponsors: University of Virginia; Bankole Johnson; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Not yet recruiting - verified May 2012
Ozurdex With Rescue Lucentis for Treating Swelling of the Retina for Your Condition

Condition: Retinal Vein Occlusion
Intervention: Drug: Dexamethasone with rescue ranibizumab
Sponsors: Wills Eye; Wills Eye
Not yet recruiting - verified April 2012
The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aprepitant; Drug: placebo
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center
Recruiting - verified April 2012
Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass

Conditions: Congenital Heart Disease; Disorder of Fetus or Newborn
Interventions: Drug: Methylprednisolone; Drug: Placebo
Sponsors: Medical University of South Carolina; Medical University of South Carolina; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)
Not yet recruiting - verified April 2012
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

Condition: Healthy
Interventions: Drug: Ondansetron; Drug: Ondansetron + Hylenex; Drug: Zofran ODT; Drug: Ondansetron solution
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified April 2012
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema

Conditions: Diabetic Macular Edema.; Non-proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathy
Interventions: Drug: dexamethasone intravitreal implant; Drug: intravitreal bevacizumab
Sponsors: Retina Macula Institute; Retina Macula Institute; Allergan
Recruiting - verified April 2012
Use of Prokinetics in Early Enteral Feeding in Preterm Infants

Conditions: Feeding Disorder; Nutrition Disorder; Infant,Premature
Interventions: Drug: Metclopramide; Drug: Erythromycin; Drug: placebo
Sponsors: East Tennessee State University; East Tennessee State University
Recruiting - verified March 2012
Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery

Conditions: Orthostatic Hypotension; Hemodynamic Instability; Fever; Hypothermia
Interventions: Drug: Hydrocortisone; Drug: Hydrocortisone
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified March 2012
Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Patients With Nausea

Condition: Nausea and Vomiting
Interventions: Drug: lorazepam; Drug: diphenhydramine hydrochloride; Drug: haloperidol; Other: placebo
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified March 2012
Improving White Blood Cell Collection From Healthy Donors

Conditions: Blood Donor; Leukocyte Transfusion; Granulocyte Colony-Stimulation Factor; Blood Component Removal
Interventions: Drug: Filgrastim (G-CSF); Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified February 2012
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

Condition: Multiple Myeloma
Interventions: Drug: DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Procedure: Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan); Procedure: Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan); Drug: Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Drug: Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12); Drug: Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)
Sponsors: University of Iowa; University of Iowa; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery

Condition: Postoperative Complications
Interventions: Drug: Placebo-saline; Drug: Dexamethasone 4 mg; Drug: Dexamethasone 8 mg
Sponsors: NorthShore University HealthSystem Research Institute; NorthShore University HealthSystem Research Institute
Recruiting - verified March 2012
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis

Condition: AL Amyloidosis
Interventions: Drug: Pomalidomide; Drug: Dexamthasone
Sponsors: Boston Medical Center; Boston Medical Center; Celgene Corporation
Not yet recruiting - verified February 2012
Oral Versus Transdermal Ondansetron for Women With Cervical Cancer Receiving Chemoradiation

Condition: Cancer of the Cervix
Interventions: Drug: Granisetron; Drug: Ondansetron; Behavioral: Questionnaires; Behavioral: Study Drug Diary
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Sancuso
Recruiting - verified March 2012
Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block

Conditions: Shoulder Pain; Injury of Shoulder Region; Disorder of Shoulder; Disorder of Rotator Cuff; Disorder of Tendon of Biceps
Interventions: Drug: Dexamethasone; Drug: Bupivacaine
Sponsors: Lifespan; Lifespan; Tufts Medical Center; United States Naval Medical Center, Portsmouth
Not yet recruiting - verified March 2012
A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Pegylated Liposomal Doxorubicin (PLD); Drug: Dexamethasone
Sponsors: Oncotherapeutics; Oncotherapeutics; Celgene Corporation
Recruiting - verified February 2012
Continuous Subpleural Infusion of Bupivacaine

Condition: Postoperative Pain.
Interventions: Drug: Subpleural pain catheter with infusion of 0.125% bupivacaine; Drug: Standard acute pain management
Sponsors: Inova Health Care Services; Inova Health Care Services
Not yet recruiting - verified February 2012
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: carfilzomib; Drug: Dexamethasone; Drug: Clarithromycin; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Lenalidomide
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Onyx Therapeutics, Inc.
Not yet recruiting - verified March 2012
5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence

Conditions: Opioid Withdrawal; Physical Dependence
Intervention: Drug: Ondansetron
Sponsors: Stanford University; Stanford University; National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2012
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

Condition: Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Siltuximab; Drug: Dexamethasone; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Janssen Services, LLC
Recruiting - verified May 2012
The Effects of Antihistamines on Pre-Pulse Inhibition

Condition: Healthy
Interventions: Drug: Placebo; Drug: Meclizine; Drug: Meclizine
Sponsors: Duke University; Duke University; Wallace Foundation
Recruiting - verified February 2012
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma

Conditions: Cholangiocarcinoma; Liver Neoplasms
Interventions: Drug: floxuridine, dexamethasone; Drug: floxuridine, dexamethasone, gemcitabine hydrochloride; Drug: floxuridine, dexamethasone, gemcitabine hydrochloride, oxaliplatin
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified May 2012
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: dalteparin; Drug: lenalidomide; Drug: dexamethasone; Other: laboratory biomarker analysis
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified January 2012
Duration of Leg Nerve Blocks With Dexamethasone Added to Local Anesthetic

Conditions: Pain; Total Knee Arthroplasty
Interventions: Drug: Dexamethasone; Drug: Ropivacaine
Sponsors: University of New Mexico; University of New Mexico
Not yet recruiting - verified April 2012
Aprepitant Effects in Intravenous Heroin Dependence

Condition: Opioid Dependence
Interventions: Drug: Aprepitant; Drug: Placebo pill
Sponsors: New York University; New York University; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012
ACE-011 With Lenalidomide+Dexamethasone for Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: ACE-011; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified May 2012
Reletex Versus Standard of Care Therapy for Post-Operative Nausea Control in Patients Undergoing Foregut Surgery

Condition: Nausea and Vomiting Post-foregut Surgery
Intervention: Device: Reletex
Sponsors: Ohio State University; Kyle A Perry
Recruiting - verified January 2012
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

Condition: Anterior Uveitis
Interventions: Drug: 40 mg/mL Dexamethasone phosphate ophthalmic solution; Drug: Prednisolone Acetate (1%) Eyedrops; Drug: 100 mM sodium citrate buffer solution; Drug: Placebo Eyedrops
Sponsors: Eyegate Pharmaceuticals, Inc.; Eyegate Pharmaceuticals, Inc.
Recruiting - verified May 2012
A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)

Condition: Postoperative Nausea and Vomiting
Interventions: Drug: Ondansetron; Drug: Vestipitant
Sponsors: Octagon Research Solutions, Inc.; Octagon Research Solutions, Inc.
Recruiting - verified May 2012
The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence

Condition: Cocaine Dependence
Interventions: Drug: Ketamine; Drug: Lorazepam (control)
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute; National Institute on Drug Abuse (NIDA)
Recruiting - verified April 2012
Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient

Condition: Agitation
Interventions: Drug: Haloperidol; Drug: Midazolam
Sponsors: Catholic Health East; Catholic Health East
Recruiting - verified December 2011
Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens

Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalinomide and Dexamethasone
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center; Merck Sharp & Dohme Corp., Inc.
Recruiting - verified December 2011
A Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy

Condition: Chemotherapy-induced Nausea and Vomiting
Interventions: Drug: Rolapitant; Drug: Granisetron; Drug: Dexamethasone
Sponsors: Tesaro, Inc.; Tesaro, Inc.; Covance; Pharm Olam Pharmaceuticals Ltd.; Parexel; Biomedical Systems Corporation; XenoBiotic Laboratories
Recruiting - verified May 2012
Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Conditions: Gastrointestinal Cancer; Nausea Post Chemotherapy
Intervention: Drug: fosaprepitant dimeglumine
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012
A Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy

Condition: Chemotherapy-induced Nausea and Vomiting
Interventions: Drug: Rolapitant; Drug: Granisetron; Drug: Dexamethasone
Sponsors: Tesaro, Inc.; Tesaro, Inc.; Covance; Pharm Olam Pharmaceuticals Ltd.; Parexel; Biomedical Systems Corporation
Recruiting - verified May 2012
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation; Multiple Myeloma Research Consortium
Recruiting - verified April 2012
Phase 3 Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy

Condition: Chemotherapy-induced Nausea and Vomiting
Interventions: Drug: Rolapitant; Drug: Granisetron; Drug: dexamethasone
Sponsors: Tesaro, Inc.; Tesaro, Inc.; Pharm Olam Pharmaceuticals Ltd.; Parexel; Covance; Biomedical Systems Corporation; XenoBiotic Laboratories
Recruiting - verified May 2012
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL)

Conditions: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Interventions: Drug: High Dose Methylprednisolone; Drug: Ofatumumab; Drug: Lenalidomide; Drug: Sargramostim
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; GlaxoSmithKline; Celgene Corporation
Recruiting - verified January 2012
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: High Dose Methylprednisolone; Drug: Ofatumumab; Drug: Lenalidomide; Drug: Sargramostim
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; GlaxoSmithKline; Celgene Corporation
Recruiting - verified January 2012
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

Conditions: Sarcoma; Chemotherapy-induced Nausea and Vomiting; Effects of Chemotherapy; Adverse Effects of Medical Drugs
Interventions: Drug: Fosaprepitant; Drug: Dexamethasone; Drug: 5HT3 receptor antagonist; Drug: Ifosfamide-based chemotherapy (AI); Drug: Doxorubicin; Drug: Mesna; Drug: Ifosfamide; Drug: Vincristine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Not yet recruiting - verified March 2012
Metabolic Effects of Olanzapine in Healthy Males

Condition: Healthy
Interventions: Drug: Olanzapine; Drug: Placebo
Sponsors: State University of New York at Buffalo; State University of New York at Buffalo
Recruiting - verified December 2011
Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema

Condition: Macular Edema
Interventions: Drug: dexamethasone Intravitreal Implant; Drug: ranibizumab
Sponsors: Allergan; Allergan
Recruiting - verified May 2012
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Conditions: Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Biological: ofatumumab; Drug: cyclophosphamide; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: cytarabine; Procedure: autologous hematopoietic stem cell transplantation; Drug: methotrexate
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified April 2012
The Effect of Systemic or Perineural Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine

Condition: Duration of Interscalene Block
Interventions: Other: ropivacaine plus dexamethasone anesthetic; Other: ropivacaine plus saline plus dexamethasone anesthetic
Sponsors: The Cleveland Clinic; The Cleveland Clinic
Recruiting - verified December 2011
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy

Conditions: Pre-diabetes; Impaired Fasting Glucose; Impaired Glucose Tolerance
Intervention: Drug: Dexamethasone
Sponsors: University of Vermont; University of Vermont; Merck
Not yet recruiting - verified December 2011
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Ganetespib Dexamethasone; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Emory University; Emory University; Multiple Myeloma Research Consortium
Recruiting - verified March 2012
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Conditions: Acute Lymphoblastic Leukemia; Precursor B-Cell Lymphoblastic Leukemia; Precursor T-Cell Lymphoblastic Leukemia
Interventions: Drug: Decitabine; Drug: Vorinostat; Drug: Vincristine; Drug: Dexamethasone; Drug: Mitoxantrone; Drug: Pegaspargase; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified March 2012
Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: Loyola University; Loyola University
Recruiting - verified December 2011
Cortisol Supression and Startle Responses in Posttraumatic Stress Disorder (PTSD)

Condition: PTSD
Interventions: Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Emory University; Emory University; National Institute of Mental Health (NIMH)
Recruiting - verified November 2011
Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.

Condition: Cataract
Interventions: Drug: Loteprednol etabonate; Drug: Prednisolones acetate
Sponsors: Bausch & Lomb, Inc.; Bausch & Lomb, Inc.
Not yet recruiting - verified November 2011
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)

Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012
Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy After Femoropopliteal Revascularization

Condition: Peripheral Arterial Disease
Intervention: Procedure: Administration of dexamethasone to SFA/popliteal adventitia
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified January 2012
Aprepitant Vesus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting

Conditions: PONV; Nausea
Interventions: Drug: Aprepitant; Drug: Ondansetron
Sponsors: Ohio State University; Sergio Bergese
Recruiting - verified November 2011
Prochlorperazine Versus Prochlorperazine & Ketorolac in Treatment of Pediatric Migraine in the Emergency Department

Condition: Migraine
Interventions: Drug: Ketorolac; Drug: Placebo
Sponsors: Akron Children's Hospital; Akron Children's Hospital
Recruiting - verified February 2012
Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

Conditions: Macular Edema; Cystoid Macular Edema; Uveal Melanoma; Radiation Maculopathy; Radiation Retinopathy
Intervention: Drug: Ozurdex (Dexamethasone intravitreal implant )
Sponsors: Wills Eye; Arman Mashayekhi; Allergan
Not yet recruiting - verified November 2011
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012
Efficacy and Safety of Masitinib in Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: masitinib 6 mg/kg/day; Drug: placebo
Sponsors: AB Science; AB Science
Recruiting - verified November 2011
A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Pomalidomide; Drug: Dexamethasone
Sponsors: Academic Myeloma Consortium; Academic Myeloma Consortium; CORE Science Solutions; Onyx Pharmaceuticals; Celgene Corporation
Recruiting - verified February 2012
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

Conditions: CLL; SLL
Interventions: Drug: Ofatumumab; Drug: High-Dose Methylprednisolone; Drug: Alemtuzumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified December 2011
FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer

Condition: Lung Cancer
Interventions: Drug: DOTAP:Chol-fus1; Drug: Erlotinib; Drug: Dexamethasone; Drug: Diphenhydramine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Convergen LifeSciences, Inc.
Not yet recruiting - verified March 2012
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Conditions: Nausea; Vomiting; Glioma
Interventions: Drug: Aprepitant and Ondansetron; Drug: Ondansetron
Sponsors: Duke University; Duke University; Merck
Not yet recruiting - verified March 2012
Ropivacaine Block Alone or With Perineural or Systemic Dexamethasone for Pain in Shoulder Surgery

Condition: Interscalene Blockade in Elective Arthroscopic Rotator Cuff Repair
Interventions: Drug: Ropivacaine; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Normal saline; Drug: Normal saline
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2012
Effect of Intraoperative Anesthetic Management on Postoperative Nausea and Vomiting in Bariatric Surgery

Condition: Postoperative Nausea and Vomiting
Interventions: Drug: general balanced anesthesia; Drug: TIVA NoNarc
Sponsors: Coastal Anesthesiology Consultants; Coastal Anesthesiology Consultants
Recruiting - verified November 2011
Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

Conditions: Retinal Vein Occlusion; Macular Edema
Interventions: Drug: Ozurdex; Drug: Ozurdex
Sponsors: Retina Macula Institute; Retina Macula Institute; Allergan
Recruiting - verified April 2012
Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)

Condition: Cornea Transplant Recipients
Interventions: Drug: Prednisolone acetate; Drug: Fluorometholone
Sponsors: Price Vision Group; Price Vision Group
Recruiting - verified April 2012
Meclizine as a Potential Smoking Cessation Treatment

Condition: Smoking Cessation
Interventions: Drug: Meclizine; Drug: Nicotine patches
Sponsors: Duke University; Duke University; Philip Morris USA, Inc.
Recruiting - verified March 2012
Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

Condition: Scleroderma
Interventions: Procedure: Rituximab sandwich regiment followed by SCT; Procedure: cyclophosphamide regiment followed by SCT
Sponsors: Northwestern University; Richard Burt, MD
Recruiting - verified April 2012
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia

Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Dexamethasone; Drug: Carfilzomib; Drug: Rituximab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Onyx Pharmaceuticals
Recruiting - verified November 2011
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Condition: Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone; Behavioral: Symptom Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Not yet recruiting - verified March 2012
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Palonosetron; Drug: Palonosetron; Drug: Ondansetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA
Recruiting - verified May 2012
A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users

Condition: Healthy Volunteer
Interventions: Drug: RO4917838; Drug: diazepam; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery

Conditions: Surgery; Pain
Interventions: Drug: .9 normal saline; Drug: 25 mg diphenhydramine IV; Drug: 50 mg diphenhydramine IV
Sponsors: Northwestern University; Northwestern University
Recruiting - verified February 2012
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Condition: Myeloma
Interventions: Drug: Pomalidomide; Drug: Dexamethasone; Drug: Cyclophosphamide
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified May 2012
Sustaining Remission of Psychotic Depression

Condition: Psychotic Depression
Interventions: Drug: Olanzapine; Drug: Placebo
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; University of Toronto; University of Massachusetts, Worcester; University of Pittsburgh
Recruiting - verified March 2012
Acupuncture and Nausea/Vomiting in Pediatric Patients

Condition: Postoperative Vomiting and Nausea
Intervention: Device: Acupuncture Needle
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified August 2011
Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ponatinib; Drug: G-CSF (Filgrastim); Drug: Rituximab; Drug: Methotrexate; Drug: Cytarabine; Drug: Solu-medrol ( Methyl Prednisolone); Drug: Citrovorum (Leucovorin); Drug: Prednisone; Drug: Pegfilgrastim (Neulasta)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Ariad Pharmaceuticals
Recruiting - verified May 2012
Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Metformin; Drug: Dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011
Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Spironolactone; Drug: Dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011
Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction

Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Hydrocortisone; Drug: dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011
Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation

Conditions: Hyperandrogenemia; Polycystic Ovary Syndrome; Obesity
Interventions: Drug: Dexamethasone; Drug: Cortrosyn
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of California, San Diego
Recruiting - verified August 2011
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Leuprolide; Drug: Dexamethasone; Drug: recombinant human chorionic gonadotropin
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Hydrocortisone; Drug: dexamethasone; Drug: Cosyntropin (ACTH)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011
Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder
Interventions: Behavioral: Visual Decision Aid and Shared Decision Making Model; Behavioral: Usual Care
Sponsors: VA Nebraska Western Iowa Health Care System; VA Nebraska Western Iowa Health Care System; New England MIRECC; Nebraska Educational Biomedical Research Association
Recruiting - verified August 2011
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Condition: Lymphoblastic Lymphoma
Interventions: Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine; Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine; Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine; Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide; Drug: Intrathecal chemotherapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National University, Singapore
Recruiting - verified April 2012
Ovarian Contribution to Androgen Production in Adolescent Girls

Conditions: Polycystic Ovary Syndrome; Obesity; Hyperandrogenism
Interventions: Drug: Dexamethasone; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia; University of California, San Diego
Recruiting - verified August 2011
A Pharmacokinetic Study of a Single-Dose of DZNS in Adult Epileptic Patients Experiencing a Seizure Episode

Condition: Epilepsy
Intervention: Drug: Diazepam
Sponsors: Neuronex, Inc.; Neuronex, Inc.
Recruiting - verified November 2011
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: GSK2110183; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: methotrexate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Proteasome Inhibitor MLN9708 in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

Condition: Multiple Myeloma
Interventions: Drug: proteasome inhibitor MLN9708; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2012
Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin

Condition: Leukemia
Interventions: Drug: ATRA; Drug: ATO; Drug: GO (Gemtuzumab ozogamicin); Drug: Methylprednisolone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified March 2012
Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis

Condition: Blepharitis
Interventions: Drug: ISV-502; Drug: Azasite; Drug: Dexamethasone; Other: Vehicle
Sponsors: InSite Vision; InSite Vision
Recruiting - verified April 2012
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); Celgene Corporation; Onyx Therapeutics, Inc.
Recruiting - verified July 2011
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: dexamethasone; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: pegaspargase; Drug: temsirolimus; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane

Conditions: Epiretinal Membrane; Macular Edema
Intervention: Drug: Dexamethasone Intravtireal Implant
Sponsors: Barnes Retina Institute; Barnes Retina Institute; Allergan
Recruiting - verified April 2012
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

Condition: Postoperative Nausea and Vomiting
Interventions: Drug: Palonosetron; Drug: Ondansetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA
Recruiting - verified January 2012
Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine

Condition: Myeloma
Interventions: Drug: Hydroxychloroquine; Drug: Rapamycin
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Drug: Lenalidomide; Drug: Lenalidomide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
Developing Individualized Strategies to Prevent Nausea and Vomiting

Conditions: Postoperative Nausea and Vomiting; Genetic Polymorphisms
Interventions: Drug: Ondansetron; Drug: Lorazepam; Drug: Aprepitant
Sponsors: University of California, San Francisco; University of California, San Francisco; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Corticosteroids for Children With Febrile Urinary Tract Infections

Conditions: Acute Urinary Tract Infection; Urinary Tract Infection
Interventions: Drug: Placebo; Drug: Dexamethasone
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Condition: Kidney Cancer
Interventions: Drug: Pazopanib; Drug: Temsirolimus; Behavioral: Quality of Life Assessment; Drug: Benadryl
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Not yet recruiting - verified March 2012
Study of Oral MLN9708 in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: MLN9708 + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Conditions: Light Chain Deposition Disease (LCDD or MIDD); Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD); Monoclonal Immunoglobulin Deposition Disease (MIDD); Amyloidosis
Intervention: Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Conditions: Cognitive/Functional Effects; Fatigue; Lymphoma; Neurotoxicity; Therapy-related Toxicity
Interventions: Biological: rituximab; Drug: bortezomib; Drug: dexamethasone; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

Condition: Relapsed Multiple Myeloma
Interventions: Drug: Lenalidomide 15mg; Drug: Lenalidomide 25mg
Sponsors: Boston VA Research Institute, Inc.; Boston VA Research Institute, Inc.; Celgene Corporation; Kansas City Veteran Affairs Medical Center; VA Pittsburgh Healthcare System; VA Greater Los Angeles Healthcare System; Michael Debakey Veterans Affairs Medical Center; Edward Hines Jr. VA Hospital
Recruiting - verified September 2011
A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Netupitant and Palonosetron; Drug: Aprepitant and Palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011
Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Tadalafil, Cialis
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012
Arry-520 + Carfilzomib for Multiple Myeloma (MM)

Condition: Myeloma
Interventions: Drug: Arry-520; Drug: Carfilzomib; Drug: Dexamethasone; Drug: Filgrastim
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Array BioPharma; Onyx Therapeutics, Inc.
Recruiting - verified February 2012
Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL)

Conditions: Leukemia; Acute Lymphoblastic Leukemia
Interventions: Drug: Inotuzumab Ozogamycin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Mesna; Drug: Vincristine; Drug: Dexamethasone; Drug: Pegfilgrastim; Drug: Methotrexate; Drug: Ara-C; Drug: Inotuzumab Ozogamycin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified April 2012
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients

Condition: Chemotherapy-induced Nausea and Vomiting
Intervention: Drug: Palonosetron, ondansetron, dexamethasone
Sponsors: Northside Hospital, Inc.; Northside Hospital, Inc.; Blood and Marrow Transplant Group of Georgia
Recruiting - verified March 2012
A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Prednisolone; Drug: dipyridamole; Drug: Prednisone; Drug: prednisolone-dipyridamole; Other: placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified June 2011
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting

Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Oral palonosetron; Drug: I.V. palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011
Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)

Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ofatumumab; Drug: Methotrexate; Drug: Cytarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2012
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Patients (MK-0869-208 AM1)

Condition: Chemotherapy Induced Nausea and Vomiting
Interventions: Drug: Aprepitant 125 mg; Drug: Aprepitant 80 mg; Drug: Aprepitant PFS; Drug: Ondansteron; Drug: Placebo for Aprepitant 125 mg; Drug: Placebo for Aprepitant 80 mg; Drug: Placebo for Aprepitant PFS
Sponsors: Merck; Merck
Recruiting - verified May 2012
Phase I/II Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Amrubicin; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Aspirin
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified October 2011
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Biological: Anti-CXCR4 (BMS-936564); Biological: Lenalidomide; Biological: Dexamethasone; Biological: Anti-CXCR4 (BMS-936564); Biological: Bortezomib; Biological: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified August 2011
Acupressure in Controlling Nausea in Young Patients With Central Nervous System or Solid Tumors Receiving Cisplatin-Containing Chemotherapy

Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: acupressure therapy; Procedure: sham intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011
Nabilone for Cannabis Dependence: A Pilot Study

Conditions: Cannabis Dependence; Marijuana Dependence
Interventions: Drug: Nabilone; Drug: Placebo
Sponsors: Mclean Hospital; Mclean Hospital; National Institute on Drug Abuse (NIDA)
Recruiting - verified January 2012
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Netupitant and Palonosetron; Drug: Palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

Condition: Myeloma
Intervention: Drug: Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
Sponsors: James Graham Brown Cancer Center; Geoffry Herzig, MD
Recruiting - verified April 2012
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia

Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: Filgrastim, Ifosfamide, Etoposide, Dexamethasone, Mesna
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Metformin; Drug: Vincristine; Drug: Dexamethasone; Drug: PEG-asparaginase; Drug: Doxorubicin; Drug: Intrathecal chemotherapy
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Pediatric Cancer Foundation
Recruiting - verified April 2012
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: Rituximab; Drug: Imatinib; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Mesna; Drug: VSLI; Drug: Solu-Medrol; Drug: Methotrexate; Drug: Ara-C; Drug: G-CSF; Drug: Pegfilgrastim; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Talon Therapeutics, Inc
Not yet recruiting - verified May 2012
Research Study of ATG and Rituximab in Renal Transplantation

Condition: Acute Kidney Injury
Interventions: Drug: ATG; Drug: Rituximab; Drug: Methylprednisolone; Drug: Diphenhydramine; Drug: Acetaminophen; Drug: Tacrolimus; Drug: Sirolimus; Drug: Hydrocortisone; Drug: Prednisone
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network (ITN)
Recruiting - verified August 2011
Dexamethasone Irrigation of the Parotid Glands in Primary Sjogren's Syndrome Subjects

Conditions: Sjogren's Syndrome; Xerostomia
Intervention: Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified November 2011
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Bortezomib; Drug: Vorinostat; Drug: Dexamethasone; Drug: Methotrexate; Drug: Imatinib mesylate
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Interventions: Drug: panitumumab; Drug: Randomization to No Panitumumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Amgen
Recruiting - verified March 2012
Imexon for Relapsed Follicular and Aggressive Lymphomas

Conditions: Follicular Lymphoma; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Burkitt's Lymphoma
Intervention: Drug: Imexon
Sponsors: University of Rochester; University of Rochester; University of Arizona
Recruiting - verified June 2011
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: ACY-1215
Sponsors: Acetylon Pharmaceuticals Incorporated; Acetylon Pharmaceuticals Incorporated; The Leukemia and Lymphoma Society
Recruiting - verified April 2012
Evaluation of Addition of Dexamethasone to Transversus Abdominis Plane (TAP) Peripheral Nerve Block

Condition: Prostate CA
Interventions: Drug: Dexamethasone; Procedure: TAP block
Sponsors: Steward St. Elizabeth's Medical Center of Boston, Inc.; Steward St. Elizabeth's Medical Center of Boston, Inc.
Recruiting - verified February 2011
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center
Recruiting - verified December 2011
Extended Steroid in CAP(e)

Condition: Community Acquired Respiratory Disease Syndrome
Intervention: Drug: Methylprednisolone
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2012
A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery

Condition: Intraocular Inflammation
Intervention:
Sponsors: Associated Eye Care, Minnesota; Associated Eye Care, Minnesota; Bausch & Lomb, Inc.
Recruiting - verified June 2011
Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

Condition: Obsessive-compulsive Disorder
Interventions: Drug: Ondansetron; Drug: Placebo
Sponsors: Transcept Pharmaceuticals; Transcept Pharmaceuticals
Recruiting - verified March 2012
Trial of Steroids in Pediatric Acute Lung Injury/ARDS

Conditions: Acute Respiratory Distress Syndrome (ARDS); Acute Lung Injury (ALI)
Interventions: Drug: methylprednisolone; Drug: Normal Saline (0.9%)
Sponsors: University of Tennessee; University of Tennessee
Recruiting - verified July 2011
Anti-psychotic Medication (Stable Dose) Weight Loss Study

Condition: Obesity
Interventions: Other: Placebo; Dietary Supplement: IHBG-10
Sponsors: Avera McKennan Hospital & University Health Center; Avera McKennan Hospital & University Health Center
Not yet recruiting - verified January 2011
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Conditions: Neoplasm Metastases; Hepatic Insufficiency
Interventions: Drug: Hepatic dysfunction group; Drug: Control group
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; PharmaMar
Recruiting - verified May 2012
A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Condition: Neoplasm Metastases
Interventions: Drug: Sequence 1; Drug: Sequence 2; Drug: Sequence 1; Drug: Sequence 2
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
A Randomized Trial of Valproate Versus Ketorolac Versus Metoclopramide for Acute Migraine

Condition: Acute Migraine
Interventions: Drug: Metoclorpamide; Drug: Ketorolac; Drug: Valproate
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified April 2012
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: alemtuzumab; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide phosphate; Drug: fludarabine phosphate; Drug: leucovorin calcium; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012
Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons

Conditions: Alcohol Abuse; Alcohol Dependence
Interventions: Drug: ondansetron; Drug: placebo ondansetron; Drug: Ondansetron
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified February 2012
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Bortezomib, proteasome inhibitor; intravenous; Drug: Dexamethasone, steroid; oral; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified June 2011
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: carboplatin; Drug: carboplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified November 2011
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma

Condition: Hepatocellular Carcinoma (HCC)
Interventions: Procedure: Transcatheter arterial chemoembolization; Procedure: Stereotactic Body Radiation Therapy
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified July 2011
A Randomized Double-Blind Controlled Trial of Single Oral Dose Dexamethasone Versus Five Days of Oral Prednisone in Acute Mild to Moderate Adult Asthma

Conditions: Asthma; Reactive Airway Disease
Interventions: Drug: Dexamethasone; Drug: Prednisone
Sponsors: Alameda County Medical Center; Alameda County Medical Center
Recruiting - verified January 2012
PH III Relapse or Refractory MM - Open Label With or Without Elotuzumab

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Condition: Myeloma
Interventions: Drug: Palifermin; Drug: Dexamethasone; Drug: Gemcitabine; Drug: Busulfan; Drug: Melphalan; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
A Study of RO4917838 in Patients With Acute Exacerbation of Schizophrenia

Condition: Schizophrenia
Interventions: Drug: RO4917838; Drug: RO4917838; Drug: olanzapine; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Diazepam Vaginal Suppositories for High Tone Pelvic Floor Dysfunction.

Condition: Female Patients With High Tone Pelvic Floor Dysfunction
Interventions: Drug: Vaginal Diazepam Suppository; Drug: Placebo Suppository
Sponsors: TriHealth Inc.; TriHealth Inc.
Recruiting - verified September 2011
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

Conditions: Choroidal Neovascularization; Myopia; Punctate Inner Choroidopathy (PIC); Multifocal Choroiditis; Ocular Histoplasmosis Syndrome; Central Serous Chorioretinopathy (CSC); Angioid Streaks; Trauma, or Hereditary Eye Diseases
Interventions: Drug: Bevacizumab (Avastin; Genentech, Inc.); Drug: Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary
Recruiting - verified April 2012
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

Conditions: Macular Edema; Central Retinal Vein Occlusion
Interventions: Drug: Ozurdex; Drug: Avastin
Sponsors: Long Island Vitreoretinal Consultants; Long Island Vitreoretinal Consultants
Recruiting - verified April 2012
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

Condition: Relapsed AL Amyloidosis
Interventions: Drug: Bendamustine; Drug: Dexamethasone
Sponsors: University of Pittsburgh; University of Pittsburgh; Cephalon
Not yet recruiting - verified June 2011
Trimodality Management of T1b Esophageal Cancers

Condition: Esophageal Cancer
Interventions: Drug: Docetaxel; Drug: 5-FU; Radiation: Radiotherapy; Procedure: Esophagectomy; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Condition: Multiple Myeloma
Interventions: Drug: VELCADE; Drug: Lenalidomide; Drug: Dexamethasone; Drug: DVT prophylaxis; Drug: Bisphosphonates; Drug: Liposomal doxorubicin; Drug: Dexamethasone
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Recruiting - verified July 2011
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Condition: Refractory Multiple Myeloma
Interventions: Drug: pomalidomide; Drug: bortezomib; Drug: dexamethasone; Other: laboratory biomarker analysis; Other: gene expression analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study

Conditions: Delirium; Impaired Cognition; Long Term Psychologic Disorders
Interventions: Drug: Haloperidol; Drug: Ziprasidone; Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified December 2011
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone; Procedure: Autologous Stem Cell Transplant
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Emory University; University of Michigan; Fox Chase Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center; Barbara Ann Karmanos Cancer Institute; Duke University; University of California, San Francisco; University of Chicago; M.D. Anderson Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified July 2011
Droperidol Versus Metoclopramide for the Treatment of Primary Headaches

Condition: Primary Headaches (Includes Migraines, Tension, Cluster Headaches)
Interventions: Drug: Droperidol; Drug: Metoclopramide; Drug: Diphenhydramine
Sponsors: University of Iowa; University of Iowa
Recruiting - verified July 2011
Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification

Conditions: Pseudophakia; Cataract Surgery
Interventions: Drug: Pred Forte; Drug: Lotemax
Sponsors: Innovative Medical; Innovative Medical
Recruiting - verified October 2011
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: ocrelizumab; Drug: Placebo; Drug: methylprednisolone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

Conditions: Relapsed Lymphoma; B Cell Non-Hodgkin Lymphoma; Refractory Lymphoma; High Risk Chronic Lymphocytic Leukemia
Interventions: Drug: Rituximab; Biological: Interleukin-2; Biological: Natural killer cells; Drug: Cyclophosphamide; Drug: Methylprednisolone; Drug: Fludarabine
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Human Behavioral Pharmacology Laboratory (HBPL) Study of the Impact of the NK1 Antagonist Aprepitant (Emend®) on Stress-Induced Cocaine and Alcohol Craving

Conditions: Cocaine; Alcohol Dependence
Interventions: Drug: Aprepitant; Drug: Placebo
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011
Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol

Condition: Subsyndromal Delirium
Interventions: Drug: Haloperidol decanoate; Drug: Placebo
Sponsors: Northeastern University; Northeastern University; National Institute on Aging (NIA)
Recruiting - verified April 2012
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

Condition: Solid Tumor
Intervention: Drug: PEGPH20
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified June 2011
Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa

Condition: Anorexia Nervosa
Interventions: Drug: Olanzapine; Drug: Placebo
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute; National Institute of Mental Health (NIMH); Weill Medical College of Cornell University; University of Pittsburgh; Johns Hopkins University; University of Toronto
Recruiting - verified April 2012
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas

Conditions: Keratoconus; Ectasia; Degeneration
Interventions: Drug: Ciprofloxicine or Vigamox or other.; Drug: Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc); Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Sponsors: Innovative Medical; Innovative Medical
Recruiting - verified April 2012
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Condition: Refractory Multiple Myeloma
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: dexamethasone; Other: DNA methylation analysis; Other: gene expression analysis; Other: bone marrow aspiration; Other: immunohistochemistry staining method; Other: reverse transcriptase-polymerase chain reaction; Other: flow cytometry
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)

Condition: PCOS
Interventions: Drug: Dexamethasone and recombinant hCG; Drug: dexamethasone, human chorionic gonadotrpoin (hCG)
Sponsors: University of California, San Diego; University of California, San Diego; University of Virginia
Recruiting - verified August 2011
Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial

Condition: Gastroparesis
Interventions: Drug: Aprepitant; Drug: Placebo
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified October 2011
Conservative Therapy Versus Epidural Steroids for Cervical Radiculopathy

Condition: Cervical Radiculopathy
Interventions: Other: Gabapentin and/or Nortriptyline, Physical therapy; Procedure: Epidural Steroid Injections (ESI); Other: Combination treatment
Sponsors: Johns Hopkins University; Johns Hopkins University; Walter Reed Army Medical Center
Recruiting - verified September 2010
A Long-Term, Open-Label, Study on Schizophrenia

Condition: Schizophrenia
Interventions: Drug: LY2140023; Drug: Olanzapine; Drug: Aripiprazole; Drug: Risperidone; Drug: Quetiapine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
A Comparison of Long-acting Injectable Medications for Schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder
Interventions: Drug: haloperidol decanoate; Drug: paliperidone palmitate
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute; National Institute of Mental Health (NIMH); Duke University; University of North Carolina, Chapel Hill
Recruiting - verified January 2012
Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery

Condition: Inflammation Following Cataract Surgery
Interventions: Drug: Difluprednate 0.05% ophthalmic emulsion; Drug: Prednisolone acetate 1.0% ophthalmic suspension
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

Condition: Schizophrenia
Interventions: Drug: paliperidone; Drug: risperidone; Drug: haloperidole; Drug: perphenazine; Drug: aripiprazole; Drug: quetiapine; Drug: paliperidone palmitate; Drug: olanzapine
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC
Recruiting - verified May 2012
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: lenalidomide, bortezomib and dexamethasone; Drug: Lenalidomide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified March 2012
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Multiple Myeloma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia
Interventions: Drug: bendamustine hydrochloride; Drug: dexamethasone; Biological: filgrastim; Procedure: leukapheresis; Other: laboratory biomarker analysis; Other: flow cytometry; Drug: etoposide
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Breast Cancer
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Cyclosporine; Biological: Natural killer cells; Drug: IL-2; Drug: Methylprednisolone; Drug: Methylprednisolone; Drug: Interleukin-2
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: ATG, rabbit; Drug: Etoposide; Drug: Intrathecal Methotrexate; Drug: hydrocortisone
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified January 2012
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Erythroleukemia (M6a); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Pure Erythroid Leukemia (M6b); B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Erythroleukemia (M6); Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Splenic Marginal Zone Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Childhood Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia
Interventions: Procedure: double-unit umbilical cord blood transplantation; Other: cytogenetic analysis; Procedure: bone marrow aspiration; Other: fluorescence in situ hybridization; Drug: busulfan; Drug: cyclophosphamide; Drug: anti-thymocyte globulin; Drug: methylprednisolone; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified January 2012
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

Condition: Malignant Pleural Mesothelioma
Interventions: Drug: NGR-hTNF plus Best Investigator Choice (BIC); Drug: Placebo plus Best Investigator Choice (BIC)
Sponsors: MolMed S.p.A.; MolMed S.p.A.
Recruiting - verified December 2011
Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD

Condition: Posttraumatic Stress Disorder
Interventions: Drug: Dexamethasone; Drug: Placebo (sugar pill)
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified January 2012
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: pomalidomide; Drug: dexamethasone; Drug: rituximab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation
Recruiting - verified June 2011
Rescue Emetic Therapy for Children Having Elective Surgery

Conditions: Post Operative Nausea and Vomiting; Rescue Emetic Therapy
Interventions: Drug: Metaclopramide; Drug: Ondansetron; Drug: diphenhydramine; Drug: Saline
Sponsors: Children's Hospital of Pittsburgh; Children's Hospital of Pittsburgh
Recruiting - verified September 2009
The Use of Domperidone for Gastroparesis

Condition: Gastroparesis
Intervention: Drug: Domperidone
Sponsors: Allegiance Health; Allegiance Health
Recruiting - verified June 2011
Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study

Condition: Non-infectious, Non-necrotizing Anterior Scleritis
Interventions: Drug: Dexamethasone Phosphate Ophthalmic Solution (EGP-437); Drug: Dexamethasone phosphate ophthalmic solution
Sponsors: University of Pennsylvania; John Kempen; FDA Office of Orphan Products Development; Eyegate Pharmaceuticals, Inc.
Recruiting - verified May 2012
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

Conditions: Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: carfilzomib; Drug: cyclophosphamide; Drug: thalidomide; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone; Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2012
Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Prednisone; Drug: Dexamethasone
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified February 2012
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Condition: Refractory Multiple Myeloma
Interventions: Drug: bendamustine hydrochloride; Drug: lenalidomide; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012
Clinical 15 Months Study Comparing Monthly Pulse ACTH (Acthar Gel) Therapy With Monthly Methylprednisolone (MP, Solumedrol) for Multiple Sclerosis (MS) Patients Who Are on Regular Beta-interferons (Avonex, Betaseron or Rebif)

Condition: Multiple Sclerosis
Interventions: Drug: ACTH; Drug: Methylprednisolone
Sponsors: University of Southern California; University of Southern California; Questcor Pharmaceuticals, Inc.
Recruiting - verified July 2011
Ketoconazole and Dexamethasone in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ketoconazole, hydrocortisone; Drug: Ketoconazole, dexamethasone
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified March 2012
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

Conditions: Breakthrough Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: fosaprepitant dimeglumine; Drug: systemic chemotherapy; Other: survey administration; Procedure: quality-of-life assessment
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified May 2012
Topical Treatment of Acute Otitis Media With Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora

Conditions: Acute Otitis Media With Tympanostomy Tubes.; Healthy Subjects With Tympanostomy Tubes.
Intervention: Drug: Ciprodex (0.3% ciprofloxacin/0.1% dexamethasone)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified May 2012
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: HER2Bi-armed activated T cells; Drug: Cyclophosphamide; Other: Laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Metoclopramide Versus Ketorolac for Tension-type Headache

Condition: Headache
Interventions: Drug: Metoclopramide; Drug: Ketorolac
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified April 2012
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Condition: Amyloidosis
Intervention: Drug: Bortezomib (Velcade) and Dexamethasone
Sponsors: Boston Medical Center; Boston Medical Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2011
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: imatinib mesylate; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: vincristine sulfate; Other: pharmacological study
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2011
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

Conditions: Keratoconus; Ectasia; Degeneration
Interventions: Drug: Ciprofloxicine or Vigamox or other.; Drug: Nonsteroidal (Acular, Voltaren Xibrom, etc); Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Sponsors: Innovative Medical; Innovative Medical
Recruiting - verified February 2012
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: AEterna Zentaris; AEterna Zentaris; Dana-Farber Cancer Institute
Recruiting - verified February 2012
IMGN901 in Combination With Lenalidomide and Dexamethasone

Condition: Multiple Myeloma
Intervention: Drug: IMGN901
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified October 2011
Initial Treatment of Patients With Immune Thrombocytopenic Purpura

Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Dexamethasone USP Micronized; Drug: Prednisone
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011
Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome

Condition: Polycystic Ovary Syndrome
Interventions: Radiation: 3-D Ultrasound; Drug: hCG with and without FSH; Drug: Adrenocorticotropin (ACTH) infusion; Drug: Diazoxide and hCG
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified August 2011
Steroids After Laser Trabeculoplasty for Glaucoma

Condition: Glaucoma
Interventions: Drug: Prednisolone 1%; Drug: Diclofenac 0.1%; Drug: Artificial Tears
Sponsors: University of Miami; University of Miami; Bascom Palmer Eye Institute; University of Pittsburgh
Recruiting - verified August 2011
Study in Adolescents With Schizophrenia or Bipolar Disorder

Conditions: Bipolar I Disorder; Schizophrenia
Interventions: Drug: Olanzapine; Behavioral: Standard behavioral weight intervention; Behavioral: Intense behavioral weight intervention
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

Conditions: Leukemia; Acute Lymphocytic Leukemia
Interventions: Drug: Everolimus (RAD001); Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Mesna; Drug: Methotrexate; Drug: Ara-C (Cytarabine); Drug: Solu-Medrol; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified November 2011
Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas

Condition: Hemangioma of Infancy
Interventions: Drug: propranolol; Drug: Prednisolone
Sponsors: Children's Research Institute; Children's Research Institute
Recruiting - verified October 2011
Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy

Conditions: Nausea; Vomiting
Interventions: Drug: aprepitant; Drug: Ondansetron
Sponsors: University of Vermont; University of Vermont; Mayo Clinic; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified March 2012
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Conditions: Hematologic Diseases; Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia
Interventions: Drug: Ondansetron; Drug: Aprepitant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012
Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes

Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Docetaxel; Drug: Carboplatin; Drug: Dexamethasone; Drug: EBV-specific cytotoxic T lymphocytes
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

Conditions: Leukemia; Acute Lymphoblastic Leukemia
Intervention: Drug: Dasatinib, Mitoxantrone, Cytarabine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified January 2012
Fosaprepitant for Breakthrough Chemotherapy Induced Nausea and Vomiting

Conditions: Nausea; Vomiting
Intervention: Drug: fosaprepitant
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute
Recruiting - verified December 2011
A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Bortezomib, Dexamethasone
Sponsors: Emory University; Emory University; Merck; Celgene Corporation
Recruiting - verified April 2012
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

Conditions: Advanced Non-small Cell Lung Cancer; Postmenopausal Women
Interventions: Drug: fulvestrant (Faslodex); Drug: anastrozole (Arimidex); Drug: Bevacizumab (Avastin); Drug: Best standard of care
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified January 2012
Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease

Conditions: Graft Versus Host Disease; Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Drug: prednisone; Drug: methylprednisolone; Other: questionnaire administration
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Greater Occipital Nerve Block for Migraine Prophylaxis

Condition: Migraine Headache
Interventions: Drug: bupivicaine/methylprednisolone (Active Injection); Drug: Placebo Injection
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified November 2011
Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules

Condition: Pulmonary Nodule
Interventions: Drug: dexamethasone; Procedure: computed tomography; Radiation: fludeoxyglucose F 18
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage

Condition: Leukemia, Lymphocytic, Acute
Interventions: Drug: Methotrexate; Drug: Vincristine; Drug: PEG-l-asparaginase; Drug: Dexamethasone; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD

Conditions: Alcoholism; Alcohol Dependence; Post-Tramatic Stress Disorder; fMRI
Intervention: Drug: Aprepitant
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified December 2011
The Effect of Prescription Medications in Marijuana Users

Condition: Marijuana Abuse
Intervention: Drug: bupropion, diazepam, dronabinol, ramelteon (Investigational Drug)
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified May 2009
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

Conditions: Leukemia; Amyloidosis
Interventions: Drug: Lenalidomide; Drug: Melphalan; Drug: Dexamethasone
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified May 2012
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults

Conditions: Alcohol Abuse; Alcoholism
Interventions: Drug: Ondansetron + BASICS Plus; Drug: Placebo + BASICS Plus
Sponsors: University of Virginia; Bankole Johnson; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified February 2012
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Condition: Advanced Cancer, Various, NOS
Interventions: Drug: BMS-833923; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Bortezomib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2012
Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation

Conditions: Leukemia, Myeloid, Acute; Leukemia, Lymphoblastic, Acute; Leukemia, Myelocytic, Chronic
Interventions: Other: Allogeneic Lymphocytes; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Methylprednisolone; Drug: Cyclosporine
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies

Conditions: Non-hodgkins Lymphoma; Hodgkins Lymphoma; Multiple Myeloma
Intervention: Drug: Oncaspar, Doxil, Decadron
Sponsors: Penn State University; Penn State University
Recruiting - verified May 2012
Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RICE; Drug: GaRD Treatment
Sponsors: Loyola University; Loyola University; Genta Incorporated
Recruiting - verified September 2011
Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

Conditions: Blood Glucose; Lipids
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine; Pfizer
Recruiting - verified March 2012
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Conditions: Multiple Myeloma; Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Drug: Dexamethasone, steroid; oral
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified February 2012
A Study of Aprepitant (MK0869) in Pediatric Patients Undergoing Surgery (0869-148)

Condition: Postoperative Nausea and Vomiting
Interventions: Drug: aprepitant; Drug: Comparator: Ondansetron
Sponsors: Merck; Merck
Recruiting - verified May 2012
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)

Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: fosaprepitant; Drug: Experimental: fosaprepitant; Drug: Experimental: fosaprepitant; Drug: Comparator: ondansetron
Sponsors: Merck; Merck
Recruiting - verified May 2012
Measurement of Pituitary Volume and Hormonal Changes in Patients With Post-traumatic Stress Disorder

Condition: Posttraumatic Stress Disorder
Interventions: Procedure: MRI of the pituitary; Procedure: DEX/CRH test
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified December 2008
Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Condition: Multiple Myeloma
Interventions: Procedure: Stem cell transplant x 1 or x 2; Drug: lenalidomide and dexamethasone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Tufts Medical Center; Lahey Clinic
Recruiting - verified January 2012
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

Condition: Psychotic Disorders
Interventions: Drug: Aripiprazole or Perphenazine; Drug: Metformin; Drug: Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, or lurasidone
Sponsors: National Institute of Mental Health (NIMH); National Institute of Mental Health (NIMH); Johns Hopkins University; University of Maryland; University of North Carolina, Chapel Hill; The Zucker Hillside Hospital
Recruiting - verified April 2012
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Biological: graft versus host disease prophylaxis/therapy; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Conditions: Multiple Myeloma; Plasma Cell Neoplasm
Interventions: Drug: Lenalidomide & Dexamethasone; Drug: Lenalidomide & Dexamethasone; Drug: Lenalidomide & Dexamethasone
Sponsors: PrECOG, LLC.; PrECOG, LLC.; Celgene Corporation
Recruiting - verified April 2012
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012
Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified May 2012
Domperidone for Refractory Gastrointestinal Disorders

Condition: Gastroparesis
Intervention: Drug: Domperidone
Sponsors: Arnold, George, M.D.; Arnold, George, M.D.
Recruiting - verified August 2011
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy

Condition: Brain Neoplasms
Intervention: Drug: Ferumoxytol
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI); AMAG Pharmaceuticals, Inc.
Recruiting - verified March 2012
UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma

Condition: Multiple Myeloma
Interventions: Drug: M-VTD-PACE; Drug: TT3-LITE Regimen (L-TT3)
Sponsors: University of Arkansas; University of Arkansas; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder

Conditions: Alcohol Dependence; Anxiety Disorder
Intervention: Drug: disulfiram plus lorazepam
Sponsors: University of New Mexico; University of New Mexico; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified January 2012
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: cyclophosphamide; Drug: dexamethasone; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2012
New Medication Treatment for Stimulant Dependence

Condition: Cocaine Dependence
Interventions: Drug: Ondansetron; Drug: Placebo
Sponsors: University of Virginia; University of Virginia; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease

Condition: Oral Chronic Graft-versus-host Disease
Interventions: Drug: Tacrolimus; Drug: Dexamethasone
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Dana-Farber Cancer Institute; Children's Hospital Boston; Beth Israel Deaconess Medical Center; Massachusetts General Hospital
Recruiting - verified February 2011
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone; Drug: lenalidomide; Drug: melphalan
Sponsors: Boston Medical Center; Boston Medical Center
Recruiting - verified February 2012
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Conditions: Leukemia; Acute Lymphoblastic Leukemia
Interventions: Drug: Rituximab; Drug: Cyclophosphamide (CTX); Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Methotrexate (MTX); Drug: Cytarabine; Drug: G-CSF; Drug: Mesna; Drug: Pegylated asparaginase; Drug: Pegfilgrastim; Drug: Solumedrol
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Conditions: Burkitt's Lymphoma; Burkitt'S-like Lymphoma
Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: G-CSF; Drug: Cytarabine; Drug: Methotrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Paclitaxel; Drug: Gemcitabine; Biological: Avastin
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Genentech
Recruiting - verified August 2011
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Biological: sargramostim; Drug: busulfan; Drug: cyclophosphamide; Drug: dexamethasone; Drug: etoposide; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation; Procedure: Bone marrow aspiration and biopsy; Procedure: Apheresis
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified January 2012
Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed By Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

Condition: Fanconi Anemia
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: fludarabine phosphate; Procedure: hematopoietic stem cell transplantation; Drug: methylprednisolone; Drug: filgrastim; Drug: cyclosporine; Drug: Mycophenolate Mofetil
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011
Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

Conditions: Neutropenia; Infection
Interventions: Drug: Standard antimicrobial therapy; Biological: Granulocyte transfusions; Drug: G-CFS/dexamethasone; Device: Apheresis machine
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011
Aloxi for Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan With Bevacizumab

Condition: Brain Cancer
Intervention: Drug: Palonosetron (Aloxi) and Dexamethasone
Sponsors: Duke University; Duke University; Eisai Inc.; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012
Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)

Condition: Status Epilepticus
Intervention: Drug: lorazepam or diazepam
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

Condition: Small Cell Lung Cancer
Interventions: Drug: Cisplatin; Drug: Etoposide; Drug: Placebo; Drug: Cisplatin; Drug: Etoposide; Drug: ZD6474
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; AstraZeneca
Recruiting - verified March 2012
Photopheresis for the Treatment of Acute Graft Versus Host Disease

Condition: Graft Versus Host Disease
Interventions: Procedure: Photopheresis; Drug: Methylprednisolone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: carboplatin; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Genetic: polymerase chain reaction; Genetic: western blotting
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011
Treatment of Orthostatic Hypotension

Conditions: Autonomic Nervous System Diseases; Orthostatic Hypotension
Interventions: Drug: droxidopa; Drug: placebo; Drug: alpha-methyldopa; Drug: carbidopa; Drug: metyrosine; Drug: levodopa; Drug: atomoxetine; Drug: metoclopramide
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified March 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
An Investigational Drug, PD 0332991, Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Condition: Multiple Myeloma
Interventions: Drug: Bortezomib; Drug: Dexamethasone; Drug: PD 0332991
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine; Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI)
Recruiting - verified May 2012
Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine

Conditions: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Obesity; Metabolic Syndrome
Intervention: Drug: olanzapine and melatonin
Sponsors: Seattle Institute for Biomedical and Clinical Research; Seattle Institute for Biomedical and Clinical Research; Eli Lilly and Company
Recruiting - verified November 2011
Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoblastic Lymphoma; Leukemia, Lymphoblastic, Acute
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Methotrexate; Drug: Vincristine; Drug: Nelarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Olanzapine in Patients With Advanced Cancer and Weight Loss

Conditions: Advanced Cancer; Weight Loss
Intervention: Drug: Olanzapine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim; Drug: dexamethasone; Drug: melphalan; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified January 2012
ALL Adult Consortium Trial: Adult ALL Trial

Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Doxorubicin; Drug: Cytarabine; Drug: Methotrexate; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Methylprednisone; Drug: Hydrocortisone Sodium Succinate; Drug: Dexamethasone; Drug: 6-MP; Drug: PEG-Asparaginase; Drug: Imatinib; Drug: Etoposide; Procedure: Radiation Therapy; Drug: E. coli Asparaginase
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; Children's Hospital Boston
Recruiting - verified August 2011
Zyprexa and Task Engagement in Schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder
Interventions: Drug: Olanzapine (Zyprexa); Drug: Typicals
Sponsors: VA Connecticut Healthcare System; VA Connecticut Healthcare System; Clinical Trials Network of Columbia U, Cornell U, and NY Presbyterian Hospital; Eli Lilly and Company
Recruiting - verified March 2012
Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks

Condition: Multiple Sclerosis
Interventions: Drug: megadose oral methylprednisolone; Drug: IV methylprednisolone
Sponsors: Mount Sinai School of Medicine; Fred Lublin; National Multiple Sclerosis Society; Pfizer
Recruiting - verified April 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease

Condition: Graft vs Host Disease
Intervention: Drug: Dexamethasone 0.01% Solution
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011
Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL

Conditions: Acute Lymphoblastic Leukemia; Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Dasatinib; Drug: Methotrexate; Drug: Ara-C
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified November 2011
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
TBI Dose De-escalation for Fanconi Anemia

Condition: Fanconi Anemia
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: anti-thymocyte globulin (ATG); Procedure: Total Body Irradiation; Procedure: Bone Marrow Transplantation; Drug: Mycophenolate Mofetil; Drug: Methylprednisolone
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Conditions: Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: stem cell transplantation; Radiation: total-body irradiation; Drug: methylprednisolone; Drug: allopurinol; Drug: filgrastim
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis

Condition: Childhood Langerhans Cell Histiocytosis
Interventions: Drug: leucovorin calcium; Drug: methotrexate; Drug: prednisolone; Drug: vinblastine sulfate
Sponsors: National Cancer Institute (NCI); Histiocyte Society
Recruiting - verified May 2007
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

Condition: Fanconi Anemia
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methylprednisolone; Biological: Hematopoietic stem cell transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Treatment of Orthostatic Hypotension in Autonomic Failure

Conditions: Autonomic Failure; Orthostatic Hypotension
Interventions: Drug: Atomoxetine; Drug: Acarbose; Drug: Pyridostigmine Bromide; Drug: Yohimbine; Drug: Midodrine HCl; Drug: placebo; Drug: Modafinil; Drug: Octreotide; Other: water intake; Drug: Diphenhydramine Hydrochloride; Drug: Ranitidine HCL; Drug: Tranylcypromine; Drug: Ergotamine/ Caffeine; Drug: Celecoxib; Drug: Pseudoephedrine; Drug: Methylphenidate; Drug: Indomethacin; Drug: Ibuprofen; Drug: Oxymetazoline 0.05% nasal solution; Dietary Supplement: Bovril; Drug: Acetazolamide; Drug: Rivastigmine tartrate; Drug: Carbidopa/levodopa; Device: abdominal binder; Device: abdominal binder (sham)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012
Autologous Transplant for Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant; Drug: Cyclophosphamide + Mesna; Drug: Melphalan; Biological: Granulocyte-colony stimulating factor; Drug: Dexamethasone
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia

Conditions: Acute Lymphoblastic Leukemia; Lymphoma, Lymphoblastic
Interventions: Drug: Etoposide, cytarabine, vincristine, dexamethasone; Drug: methotrexate, teniposide, PEG-asparaginase; Drug: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine; Drug: L-asparaginase, erwinia asparaginase; Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy; Procedure: Hematopoietic Stem Cell Transplant; Procedure: Natural Killer (NK) Cell Transplant
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified March 2012
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

Conditions: Childhood Langerhans Cell Histiocytosis; Fanconi Anemia; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: melphalan; Drug: methylprednisolone; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Milton S. Hershey Medical Center
Recruiting - verified October 2008
Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cisplatin; Drug: cytarabine; Drug: dexamethasone; Drug: gemcitabine hydrochloride; Other: clinical observation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012
Alcohol Dependency Study: Combining Medication Treatment for Alcoholism

Condition: Alcoholism
Interventions: Drug: ondansetron + cognitive behavioral therapy; Drug: topiramate + cognitive behavioral therapy; Drug: Placebo + cognitive behavioral therapy; Drug: ondansetron + topiramate + cognitive behavioral therapy
Sponsors: University of Virginia; Bankole Johnson; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified February 2012